Asset profile
RenovoCath · RenovoRx, Inc. (RNXT)
- Indication
- locally advanced pancreatic cancer (LAPC)
- Also known as
- RenovoCath®, TAMP, IAG, intra-arterial gemcitabine
Company
RNXTRenovoRx, Inc.
RNXTRenovoRx, Inc.RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arteri…
On the calendar
13
Aug 2026
Aug 13, 2026
79 days ago
RNXTRenovoRx, Inc.Timeline
Newest first.
Aug 4, 2026
08:10 PM
RNXTRenovoRx, Inc.RenovoRx to Highlight TAMP Platform at JonesTrading KOL Webinar on Pancreatic Cancer
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT07477418 | Phase 1/2 | Not yet recruiting | Dec 1, 2030 | 10 | 1 of 1 sites in the United States |
| NCT03985007 | Phase 2 | Completed | Dec 31, 2020 | 40 | 0 of 1 sites in the United States |
| NCT03257033 | Phase 3 | Active, not recruiting | Jun 1, 2027 | 190 | 26 of 31 sites in the United States |
| NCT03786302 | Phase 2 | Terminated | Aug 15, 2018 | 102 | 0 of 1 sites in the United States |
More from RenovoRx, Inc.
Other drugs and candidates from the same company tracked in this sector.